Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21085092 | 0.83 | ALOX5 (0.42) | LMNAALOX5SLC22A6 | |
| SCHEMBL23495089 | 0.81 | LMNA (0.44) | LMNAALKBH5SUCNR1EGLN1ALOX5 | |
| SCHEMBL21085078 | 0.80 | TSHR (0.44) | LMNAALOX5SLC22A6 | |
| SCHEMBL21085157 | 0.76 | CYP4F2 (0.33) | LMNAFOLH1CYP4F2CYP4A11 | |
| SCHEMBL301024 | 0.71 | — | — | |
| SCHEMBL8920891 | 0.71 | KDM5A (0.47) | LMNAALKBH5SUCNR1EGLN1SLC22A6 | |
| SCHEMBL672141 | 0.71 | KDM5A (0.47) | LMNAALKBH5SUCNR1EGLN1SLC22A6 | |
| SCHEMBL19354999 | 0.70 | LMNA (0.38) | LMNAALKBH5SUCNR1EGLN1HTT | |
| SCHEMBL25660621 | 0.70 | LMNA (0.38) | LMNAALKBH5SUCNR1EGLN1ALOX5 | |
| SCHEMBL21085148 | 0.70 | HSD17B10 (0.30) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | GPR119, IAPP, DPP4 | LMNA 4657/4885ALKBH5 3835/4885SUCNR1 121/4885 |
| US-10759749-B2 | Therapeutic agent for diabetes | GPR119, IAPP, DPP4 | LMNA 4517/4885ALKBH5 2714/4885SUCNR1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.